For over a decade, the standard of care for high-risk MDS has remained a class of drugs called hypomethylating agents (HMAs). Borate notes that despite their continued use, there has been limited ...
Dr. Shaal Patel, a board certified physician in hematology, oncology, and internal medicine, spoke with Healthline about how myelodysplastic syndromes (MDS) can benefit from supportive therapy, ...
Myelodysplastic syndrome (MDS) is one of the most common haematological malignancies and is associated with increased age and exposure to previous chemotherapy and radiation. It is characterized by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results